NFSG
ALGS icon

Newbridge Financial Services Group’s Aligos Therapeutics ALGS Stock Holding History

Newbridge Financial Services Group’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$28 – 1135
2023
Q3 		$28 Hold
1
– – ﹤0.01% 1268
2023
Q2 		$36 Hold
1
– – ﹤0.01% 1329
2023
Q1 		$32 Hold
1
– – ﹤0.01% 1389
2022
Q4 		$35 Hold
1
– – ﹤0.01% 1421
2022
Q3 		$0 Hold
1
– – ﹤0.01% 1372
2022
Q2 		$0 Hold
1
– – ﹤0.01% 1350
2022
Q1 		$0 Hold
1
– – ﹤0.01% 1428
2021
Q4 		$0 Hold
1
– – ﹤0.01% 1399
2021
Q3 		$1K Hold
1
– – ﹤0.01% 1216
2021
Q2 		$1K Hold
1
– – ﹤0.01% 1324
2021
Q1 		$1K Buy
+1
New +$666 ﹤0.01% 1226

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACP
Altitude Crest Partners Stamford, Connecticut $234M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Newbridge Financial Services Group's ALGS Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Aligos Therapeutics (ALGS) in Q4 2023, closing a stake of 1 share — an estimated $28 sold.

Newbridge Financial Services Group first reported a position in ALGS in Q1 2021 and held it in 11 quarters. The position peaked at $1K in Q3 2021. 39 funds tracked by Wall St. Rank hold ALGS as of Q4 2023.

  • Newbridge Financial Services Group reported no remaining Aligos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 1 Aligos Therapeutics share in Q4 2023, an estimated $28.
  • Newbridge Financial Services Group first reported a position in Aligos Therapeutics in Q1 2021 and held it in 11 quarters.
  • Newbridge Financial Services Group's Aligos Therapeutics position peaked at $1K in Q3 2021.
  • 39 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.